Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02307461 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
A Phase 1 study of Healthy, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT02307461: Completed Phase 1 study of Healthy, sponsored by SecuraBio.
NCT02307461 is a Phase 1 study of Healthy that has completed, run by SecuraBio. The registered enrollment target is 103 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02307461, a Phase 1 study of Healthy, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
To Evaluate the Bioequivalence of the two formulations of IPI-145 and the Effect of Food on the Pharmacokinetics of IPI-145
Conditions Studied
Interventions
- DRUG IPI-145
- DRUG IPI-145 (duvelisib)
Study Locations (1)
Kansas
- - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
What the finished NCT02307461 record still lists
NCT02307461 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which IPI-145 is the first listed.
NCT02307461 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT02307461 about?
NCT02307461 is a clinical study titled "Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145". To Evaluate the Bioequivalence of the two formulations of IPI-145 and the Effect of Food on the Pharmacokinetics of IPI-145
What is the current status of trial NCT02307461?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2014-11. Estimated completion is 2015-09.
What conditions does trial NCT02307461 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02307461?
The interventions under investigation include: IPI-145 (DRUG), IPI-145 (duvelisib) (DRUG).
Who is sponsoring clinical trial NCT02307461?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02307461 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02307461's enrollment target sits among peer trials
103 215th of 1090 higher than 875 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia